This work was presented in abstract form at the American Society of Bone and Mineral Research meetings, Seattle, Washington, U.S.A., 1996 and Cincinnati, Ohio, U.S.A., 1997.
Zoledronate Prevents the Development of Absolute Osteopenia Following Ovariectomy in Adult Rhesus Monkeys†
Article first published online: 1 NOV 1998
Copyright © 1998 ASBMR
Journal of Bone and Mineral Research
Volume 13, Issue 11, pages 1775–1782, November 1998
How to Cite
Binkley, N., Kimmel, D., Bruner, J., Haffa, A., Davidowitz, B., Meng, C., Schaffer, V. and Green, J. (1998), Zoledronate Prevents the Development of Absolute Osteopenia Following Ovariectomy in Adult Rhesus Monkeys. J Bone Miner Res, 13: 1775–1782. doi: 10.1359/jbmr.19184.108.40.2065
- Issue published online: 4 DEC 2009
- Article first published online: 1 NOV 1998
- Manuscript Accepted: 15 JUL 1998
- Manuscript Revised: 22 JUN 1998
- Manuscript Received: 6 MAR 1998
This study assessed effects of the bisphosphonate zoledronate (ZLN) on bone density and biochemical markers of bone turnover in ovariectomized (OVX) adult female rhesus monkeys. Forty monkeys were randomly assigned to one control or four OVX groups. The control and one OVX group received saline, and the other three OVX groups received ZLN (0.5, 2.5, or 12.5 μg/kg) by a single weekly subcutaneous injection for 69 weeks. Bone mass of the total body (TB), lumbar spine (LS), distal and central radius (dual-energy X-ray absorptiometry), and skeletal turnover markers were measured at baseline and at 13, 26, 39, 52, and 69 weeks of treatment. Increased skeletal turnover and decreased bone mass (LS and TB) were demonstrable by 13 weeks post-OVX. Maximal bone loss (7–8%) at these sites occurred by 39 weeks after OVX and persisted for the study duration. Long-term ZLN treatment was well tolerated and prevented increased skeletal turnover and bone loss in a dose-dependent fashion. Progressive turnover suppression was not observed with any ZLN dose. In conclusion, after OVX, adult rhesus monkeys develop persistent increased bone turnover and absolute osteopenia of the LS and TB, making them an outstanding model of skeletal behavior in perimenopausal women. These OVX-related skeletal changes are dose-dependently blocked by ZLN.